Belzutifan + Zanzalintinib for Kidney Cancer

This trial explores a new treatment combination for advanced kidney cancer (renal cell carcinoma) to determine if it improves outcomes. Specifically, it tests whether adding zanzalintinib to belzutifan (a new potential drug) extends survival and slows cancer progression compared to belzutifan alone. Participants must have advanced kidney cancer and no more than three prior treatments for it. As a Phase 3 trial, this represents the final step before FDA approval, offering participants access to potentially groundbreaking treatment.

The trial information does not specify if you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.

Research has shown that the combination of belzutifan and zanzalintinib is generally safe for people with kidney cancer. Studies have found that patients tolerate this combination well. Specifically, those taking belzutifan and zanzalintinib have lived longer without their cancer worsening compared to those taking cabozantinib.

Unlike the standard treatments for kidney cancer, which typically involve methods like immunotherapy or chemotherapy, Belzutifan offers a unique approach by targeting the HIF-2α pathway, a key player in cancer cell survival. Researchers are excited about Belzutifan because it directly disrupts this pathway, potentially halting cancer growth more effectively. Additionally, the combination with Zanzalintinib, a tyrosine kinase inhibitor, could enhance the treatment's effectiveness by attacking the cancer cells from multiple angles, offering new hope for improved outcomes.

This trial will compare the combination of belzutifan and zanzalintinib with belzutifan and a placebo for treating advanced kidney cancer, known as renal cell carcinoma (RCC). Research has shown that combining belzutifan and zanzalintinib may be effective. Specifically, one study indicated that patients taking both medications lived longer and experienced better cancer control compared to those on other treatments. The combination achieved a 70% response rate, with many patients seeing their tumors shrink or stop growing. Patients also experienced longer periods without their cancer worsening. These results suggest that adding zanzalintinib to belzutifan could offer a more effective treatment option for advanced RCC.¹²⁴⁶⁷